EDIT vs. CRSP

In the year-to-date period, EDIT achieves a -87.07% return, which is significantly lower than CRSP's -34.95% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Editas Medicine, Inc. (EDIT) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current EDIT Sharpe Ratio is -1.15, which is lower than the CRSP Sharpe Ratio of -0.66. The chart below compares the historical Sharpe Ratios of EDIT and CRSP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither EDIT nor CRSP has paid dividends to shareholders.

The maximum EDIT drawdown since its inception was -98.55%, which is greater than CRSP's maximum drawdown of -81.61%. Use the drawdown chart below to compare losses from any high point for EDIT and CRSP. For additional features, visit the drawdowns tool.

Editas Medicine, Inc. (EDIT) has a higher volatility of 35.04% compared to CRISPR Therapeutics AG (CRSP) at 19.01%. This indicates that EDIT's price experiences larger fluctuations and is considered to be riskier than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Editas Medicine, Inc. and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.